About GenEdit

GenEdit utilizes the NanoGalaxy® delivery platform to enhance the safe and efficient delivery of CRISPR-Cas9 gene editing therapies for genetic diseases. This technology addresses the challenge of limited access to effective genetic medicines, enabling broader patient treatment options.

```xml <problem> Current CRISPR-Cas9 gene editing therapies face challenges in safe and efficient delivery, limiting their accessibility and effectiveness for treating a wide range of genetic diseases. The lack of targeted delivery mechanisms hinders the ability of these therapies to reach the intended cells and tissues, reducing their therapeutic potential. </problem> <solution> GenEdit is developing the NanoGalaxy® delivery platform to improve the delivery of CRISPR-Cas9 gene editing therapies. This platform aims to enhance the safety, specificity, and efficiency of gene editing by enabling targeted delivery of therapeutic payloads to specific cells and tissues within the body. By overcoming delivery limitations, NanoGalaxy® seeks to expand the range of treatable diseases and improve patient outcomes. The platform is designed to facilitate the development of innovative genetic medicines that can effectively edit out disease and rewrite patient health. </solution> <features> - Targeted delivery of CRISPR-Cas9 components to specific cells and tissues - Enhanced safety profile compared to traditional delivery methods - Improved efficiency of gene editing within target cells - Versatile platform applicable to a wide range of genetic diseases </features> <target_audience> The primary target audience includes researchers and pharmaceutical companies developing CRISPR-Cas9 based gene editing therapies for genetic diseases. </target_audience> ```

What does GenEdit do?

Where is GenEdit located?

GenEdit is based in South San Francisco, United States.

When was GenEdit founded?

GenEdit was founded in 2016.

How much funding has GenEdit raised?

GenEdit has raised $24.0M.

Who founded GenEdit?

GenEdit was founded by Kunwoo Lee.

Kunwoo Lee - CEO / Co-founder

Location

South San Francisco, United States

Founded

2016

Funding

$24.0M

Employees

55 employees

Investors

Bbv Dsc Investment Kerna Loftyrock Pathway Group Venture Miraeasset

GenEdit

South San Francisco, United StatesFounded 2016553K+ followers10/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.

Updated 3 months ago

Funding

$24.0M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Current CRISPR-Cas9 gene editing therapies face challenges in safe and efficient delivery, limiting their accessibility and effectiveness for treating a wide range of genetic diseases. The lack of targeted delivery mechanisms hinders the ability of these therapies to reach the intended cells and tissues, reducing their therapeutic potential.

Solution

GenEdit is developing the NanoGalaxy® delivery platform to improve the delivery of CRISPR-Cas9 gene editing therapies. This platform aims to enhance the safety, specificity, and efficiency of gene editing by enabling targeted delivery of therapeutic payloads to specific cells and tissues within the body. By overcoming delivery limitations, NanoGalaxy® seeks to expand the range of treatable diseases and improve patient outcomes. The platform is designed to facilitate the development of innovative genetic medicines that can effectively edit out disease and rewrite patient health.

Target Audience

The primary target audience includes researchers and pharmaceutical companies developing CRISPR-Cas9 based gene editing therapies for genetic diseases.

Features

Targeted delivery of CRISPR-Cas9 components to specific cells and tissues
Enhanced safety profile compared to traditional delivery methods
Improved efficiency of gene editing within target cells
Versatile platform applicable to a wide range of genetic diseases